EMBER-4: A Randomized, Open- Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence.

  • McCartney, Amelia (Primary Chief Investigator (PCI))

Project: Research

Project Details

Project Description

HREC Reference Number: HREC/89563/SVHM-2022-335264(v3)
SSA Code: SSA/89563/MonH-2023-384121(v1)
Monash Health Local Reference: RES-23-0000-487X
StatusActive
Effective start/end date29/08/23 → 28/08/28